These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 11397884)

  • 1. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis.
    Oleksik AM; Duong T; Pliester N; Asma G; Popp-Snijders C; Lips P
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2763-8. PubMed ID: 11397884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-i and insulin-like growth factor binding protein-3: a 2-year, double-blind, placebo-controlled study.
    Duschek EJ; de Valk-de Roo GW; Gooren LJ; Netelenbos C
    Fertil Steril; 2004 Aug; 82(2):384-90. PubMed ID: 15302288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study.
    Bellantoni MF; Vittone J; Campfield AT; Bass KM; Harman SM; Blackman MR
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2848-53. PubMed ID: 8768841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulatory effect of raloxifene and estrogen on the metabolic action of growth hormone in hypopituitary women.
    Birzniece V; Meinhardt U; Gibney J; Johannsson G; Baxter RC; Seibel MJ; Ho KK
    J Clin Endocrinol Metab; 2010 May; 95(5):2099-106. PubMed ID: 20207825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women.
    Gibney J; Johannsson G; Leung KC; Ho KK
    J Clin Endocrinol Metab; 2005 Jul; 90(7):3897-903. PubMed ID: 15855258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the selective oestrogen receptor modulator-raloxifene-on calcium and PTH secretory dynamics in women with osteoporosis.
    Oleksik A; Duong T; Popp-Snijders C; Pliester N; Asma G; Lips P
    Clin Endocrinol (Oxf); 2001 May; 54(5):575-82. PubMed ID: 11380487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement.
    Span JP; Pieters GF; Sweep CG; Hermus AR; Smals AG
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1121-5. PubMed ID: 10720049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
    Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
    Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unequal impact of short-term testosterone repletion on the somatotropic axis of young and older men.
    Gentili A; Mulligan T; Godschalk M; Clore J; Patrie J; Iranmanesh A; Veldhuis JD
    J Clin Endocrinol Metab; 2002 Feb; 87(2):825-34. PubMed ID: 11836328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women.
    Holloway L; Butterfield G; Hintz RL; Gesundheit N; Marcus R
    J Clin Endocrinol Metab; 1994 Aug; 79(2):470-9. PubMed ID: 7519191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
    Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
    Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.
    Laursen T; Jørgensen JO; Jakobsen G; Hansen BL; Christiansen JS
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2410-8. PubMed ID: 7543114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators.
    Birzniece V; Sutanto S; Ho KK
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E521-7. PubMed ID: 22319035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of aging and estradiol supplementation on GH axis dynamics in women.
    Lieman HJ; Adel TE; Forst C; von Hagen S; Santoro N
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3918-23. PubMed ID: 11502833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
    Guevara-Aguirre J; Rosenbloom AL; Vasconez O; Martinez V; Gargosky SE; Allen L; Rosenfeld RG
    J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
    Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.